COLL vs. XBI

In the year-to-date period, COLL achieves a 1.71% return, which is significantly higher than XBI's -12.06% return. Over the past 10 years, COLL has outperformed XBI with an annualized return of 5.21%, while XBI has yielded a comparatively lower 0.11% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Collegium Pharmaceutical, Inc. (COLL) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current COLL Sharpe Ratio is -0.26, which is higher than the XBI Sharpe Ratio of -0.39. The chart below compares the historical Sharpe Ratios of COLL and XBI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

COLL has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.17%.

The maximum COLL drawdown since its inception was -73.59%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for COLL and XBI.

The current volatility for Collegium Pharmaceutical, Inc. (COLL) is 9.41%, while SPDR S&P Biotech ETF (XBI) has a volatility of 10.41%. This indicates that COLL experiences smaller price fluctuations and is considered to be less risky than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.